Remove Dermatitis Remove Medical Remove Therapy
article thumbnail

Researchers Close In on New Topical Therapy That Suppresses Mast Cells

The Dermatology Digest

Currently, there arent a lot of good therapies that target mast cells, so we think that our approach could potentially have huge benefits in many skin conditions, including rosacea, eczema, urticaria and mastocytosis. There are no good therapies for flushing, so this is a significant unmet need.

Therapy 41
article thumbnail

New Ladder Helps Guide Choice of Non-steroidal Treatments in AD

The Dermatology Digest

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A. The study appears in Dermatitis.

article thumbnail

Thinning Eyebrows in Women Over 40: Causes and Best Treatments

Alison Bladh

Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy.

article thumbnail

Eczema (Atopic Dermatitis) vs. Psoriasis: Understanding the Differences

First Derm

Different Triggers and Causes : Eczema flare-ups can be triggered by allergens and irritants, whereas psoriasis can be exacerbated by stress, infections, and certain medications. Contact dermatitis from metals, latex, chemicals. Medications (lithium, beta-blockers, NSAIDs). 2] Why is Eczema Considered a Chronic Condition?

Eczema 59
article thumbnail

Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference?

First Derm

Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.

article thumbnail

AD Pipeline Watch: Amgen, Kyowa Kirin’s Anti-OX40 Candidate Meets Endpoints in AD Trial

The Dermatology Digest

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 42.3% difference vs. placebo. In the lower dose group, 36.3%

article thumbnail

AD Pipeline Watch: U.S. FDA Fast Tracks Nektar Therapeutics’ AD Candidate

The Dermatology Digest

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. “We are pleased that rezpegaldesleukin has been designated a Fast Track product,” says Jonathan Zalevsky, Ph.D.,